Enliven Therapeutics Inc (ELVN) Stock Analysis
Verdict: HOLD
Positive Phase 1 CML data creates a momentum floor, but recent insider selling and 212% rally suggest a cooling period is necessary.
Investment score: 64/100
Analysis as of
Is Enliven Therapeutics Inc stock worth reviewing? The TradeMates thesis
Hold for clinical momentum; wait for entry at support.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 90/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Enliven Therapeutics Inc opportunities and risks
What speaks for ELVN
- ELVN-001 Clinical Efficacy
What speaks against ELVN
- Aggressive Insider Selling
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ELVN | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.3% |
| CRNX | n/a | 201.1x | n/a | 98.9% | -2747.2% | -11.5% |
| OGN | 14.2x | 0.6x | 7.9x | 53.1% | 4.0% | 17.4% |
| ALMS | n/a | 354.8x | n/a | 89.6% | -2825.7% | -12.6% |
| GPCR | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.4% |
| DFTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.3% |
| Peer median | n/a | 0.6x | n/a | 53.1% | 0.0% | -6.4% |
Frequently asked questions about Enliven Therapeutics Inc (ELVN)
Is ELVN stock a good investment?
The TradeMates model rates Enliven Therapeutics Inc as HOLD with an investment score of 64/100. Hold for clinical momentum; wait for entry at support. This is algorithmic model output, not personal investment advice.
Is ELVN stock a buy?
The TradeMates model verdict for ELVN is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.